# A Comparison of the Effectiveness and Safety of Injectable Risperidone With That of Risperidone Tablets in the Treatment of Patients With Chronic Schizophrenia

> **NCT00249223** · PHASE3 · COMPLETED · sponsor: **Janssen Pharmaceutica N.V., Belgium** · enrollment: 641 (actual)

## Conditions studied

- Schizophrenia
- Psychotic Disorders

## Interventions

- **DRUG:** Risperidone Long acting injectable

## Key facts

- **NCT ID:** NCT00249223
- **Lead sponsor:** Janssen Pharmaceutica N.V., Belgium
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-01
- **Primary completion:** —
- **Final completion:** 2000-12
- **Target enrollment:** 641 (ACTUAL)
- **Last updated:** 2011-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00249223

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00249223, "A Comparison of the Effectiveness and Safety of Injectable Risperidone With That of Risperidone Tablets in the Treatment of Patients With Chronic Schizophrenia". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00249223. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*